Comparative analysis of fingolimod versus teriflunomide in relapsing–remitting multiple sclerosis
Articles > Article · 2019
Authors: C Boz, M Terzi, B Özer, R Turkoglu, R Karabudak, H Efendi, A Soysal, S Sevim, A Altintas, A Kurne, A Akçalı, G Akman, Ayşe Nur YÜCEYAR, BP Balcı, Özgül EKMEKCİ, SZ Karahan, M Demirkıran, B Altunrende, ÖF Turan, GözübatıkÇelik Gökçen, N Kale, M Köseoğlu, S Ozakbas
Multiple Sclerosis and Related Disorders, Journal Indexed in SCI Expanded, International, WoS, 2019, vol 36, pp 101376-101376
DOI: 10.1016/j.msard.2019.101376
Summary
Background: Fingolimod and teriflunomide are commonly used in the treatment of relapsing-remitting multiple sclerosis (RRMS). These have not been compared in controlled trials, but only in observational studies, with inconclusive results. Comparison of their effect on relapse and disability in a real-world setting is therefore needed.